Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (151-160 of 228) with videos related to

Pageof 23
Sort By:
Breast Care (Basel, Switzerland)|October 9, 2025
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2014
Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility studyKatja Pinker, Wolfgang Bogner, Pascal Baltzer, et al.
Cancer Treatment Reviews|November 29, 2024
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancerVolkmar Müller, Thomas Bachelot, Giuseppe Curigliano, et al.
Investigative Radiology|October 26, 2018
Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer PatientsAmirhessam Tahmassebi, Georg J Wengert, Thomas H Helbich, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2014
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyMathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, et al.
Clinical Breast Cancer|July 22, 2015
Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel ChemotherapyRegina Promberger, Peter Dubsky, Martina Mittlböck, et al.
Breast (Edinburgh, Scotland)|May 7, 2026
HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patientsSandra Mayer, Anna Pfarrhofer, Sophie M Neubauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2023
Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung CancerErwin Tomasich, Ariane Steindl, Christina Paiato, et al.
BMC Cancer|October 20, 2009
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancerRupert Bartsch, Catharina De Vries, Ursula Pluschnig, et al.
Cancer Medicine|May 31, 2024
Prevalence and biopsychosocial indicators of fatigue in cancer patientsElisabeth L Zeilinger, Irina Zrnic-Novakovic, Claudia Oppenauer, et al.
Pageof 23

Showing results (151-160 of 228) with videos related to

Sort By:
Pageof 23
Breast Care (Basel, Switzerland)|October 9, 2025
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2014
Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility studyKatja Pinker, Wolfgang Bogner, Pascal Baltzer, et al.
Cancer Treatment Reviews|November 29, 2024
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancerVolkmar Müller, Thomas Bachelot, Giuseppe Curigliano, et al.
Investigative Radiology|October 26, 2018
Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer PatientsAmirhessam Tahmassebi, Georg J Wengert, Thomas H Helbich, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2014
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyMathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, et al.
Clinical Breast Cancer|July 22, 2015
Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel ChemotherapyRegina Promberger, Peter Dubsky, Martina Mittlböck, et al.
Breast (Edinburgh, Scotland)|May 7, 2026
HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patientsSandra Mayer, Anna Pfarrhofer, Sophie M Neubauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2023
Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung CancerErwin Tomasich, Ariane Steindl, Christina Paiato, et al.
BMC Cancer|October 20, 2009
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancerRupert Bartsch, Catharina De Vries, Ursula Pluschnig, et al.
Cancer Medicine|May 31, 2024
Prevalence and biopsychosocial indicators of fatigue in cancer patientsElisabeth L Zeilinger, Irina Zrnic-Novakovic, Claudia Oppenauer, et al.
Pageof 23